For instance, Pfizer launched the phase II research of the experimental C. difficile vaccine candidate, PF-06425090, in January 2017. It is intended to prevent C. difficile infection. This randomised phase II trial was carried out to investigate the immunogenicity, safety, and tolerability of the Clostridium Vaccine Market in healthy people between the ages of 65 and 85. In March 2017, Pfizer started a phase III research with over 16,000 participants.
The phase II clinical research for Valneva SE's prophylactic vaccine candidate VLA84, which focuses on the primary prevention of C. difficile infection, was successfully completed in July 2016. (CDI).
Read More:
https://knackersblogger.blogspot.com/2023/03/clostridium-vaccine-market-global.html
